Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03233399 · ClinicalTrials.gov registry record · NA

Modulating Movement Intention Via Cortical Stimulation

A NA study of Seizures and Seizure Disorder, sponsored by NYU Langone Health.

Recruiting
Registry status
NA
Development phase
30
Enrollment target
1
Study location

NCT03233399 is a NA study of Seizures and Seizure Disorder that is actively recruiting participants, run by NYU Langone Health. The registered enrollment target is 30 participants, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03233399, a NA study of Seizures and Seizure Disorder, is actively recruiting participants, sponsored by NYU Langone Health.

RECRUITING
Registry status
NA
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of plasticity-inducing treatments for PMD symptoms.

Interventions

  • DEVICE Sham TMS3 stimulation
  • DEVICE rTMS of left or right angular gyrus (AG) or frontal cortex (FC)
  • DEVICE Anodal tDCS of left or right AG or FC

Study Locations (1)

New York

  • New York University School of Medicine - New York

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2017-07-20
Est. Completion 2027-05
Phase NA

Sponsor

NYU Langone Health

1,164 total trials

What the Registry Record Tells You About NCT03233399

The ClinicalTrials.gov registry entry for NCT03233399 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 934-participant average among 39 other Seizures trials with a reported enrollment target (97% lower). The listed sponsor is NYU Langone Health, which has 1,164 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Seizures appearing as the primary indexed condition, and to 3 interventions - of which Sham TMS3 stimulation is the first listed.

NCT03233399 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT03233399 about?

NCT03233399 is a clinical study titled "Modulating Movement Intention Via Cortical Stimulation". The purpose of this protocol is to learn about movement intention and volition. To improve such knowledge, investigators will conduct sub-studies using multiple non-invasive methodologies. These results could provide preliminary data for subsequent studies evaluating local and global efficacy of pla...

What is the current status of trial NCT03233399?

This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2017-07-20. Estimated completion is 2027-05.

What conditions does trial NCT03233399 study?

This clinical trial studies the following conditions: Seizures, Seizure Disorder, Psychogenic Movement Disorder.

What interventions are being tested in trial NCT03233399?

The interventions under investigation include: Sham TMS3 stimulation (DEVICE), rTMS of left or right angular gyrus (AG) or frontal cortex (FC) (DEVICE), Anodal tDCS of left or right AG or FC (DEVICE).

Who is sponsoring clinical trial NCT03233399?

This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03233399 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Seizures

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.